Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JW-65
- Development stage
- Preclinical
- Lead developer
- SEAK Therapeutics
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intravenous, Oral
01
Overview
JW-65 is a potent, selective, and brain-penetrant small-molecule inhibitor of transient receptor potential canonical 3 (TRPC3) channels. Developed by SEAK Therapeutics in collaboration with researchers at the University of Tennessee Health Science Center (UTHSC), JW-65 was optimized from the prototypic TRPC3 inhibitor pyrazole 3 (Pyr3) to improve metabolic stability and reduce toxicity. It is being investigated for the treatment of epilepsy (including inherited generalized tonic-clonic epilepsy and chemoconvulsant-induced seizures) and Alzheimer's disease, where it has demonstrated neuroprotective effects by mitigating calcium overload and reducing beta-amyloid-induced synaptic dysfunction.
02
Targets
TRPC3
Beyond the preview
Go deeper on JW-65.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW-65.